Palliative thoracic radiotherapy for lung cancer

References

• Hawson G, Zimmerman PV, Ford CA, Johnston NG, Firouz-Abadi A. Primary lung cancer: characterization and survival of 1024 patients treated in a single institution. Med. J. Aust.152(5), 230–234 (1990).
   PubMedGoogle Scholar
• Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother. Oncol.83(2), 203–213 (2007).
   PubMed Web of Science ®Google Scholar
• Fairchild A, Harris K, Barnes E et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J. Clin. Oncol.26(24), 4001–4011 (2008).
   PubMed Web of Science ®Google Scholar
• Budach W, Belka C. Palliative percutaneous radiotherapy in non-small-cell lung cancer. Lung Cancer45(2), S239–S245 (2004).
   Google Scholar
• Bezjak A, Dixon P, Brundage M et al. Randomized Phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer. Int. J. Radiat. Oncol. Biol. Phys.54(3), 719–729 (2002).
   PubMedGoogle Scholar
• Kramer GW, Wanders SL, Noordijk EM et al. Results of the Dutch national study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J. Clin. Oncol.23(13), 2962–2970 (2005).
   PubMedGoogle Scholar
• Senkus-Konefka E, Dziadziuszko R, Bednaruk-Mlynski et al. A prospective randomised study to compare two palliative radiotherapy schedules for non-small cell lung cancer (NSCLC). Br. J. Cancer92(6), 1038–1045 (2005).
   PubMedGoogle Scholar
• Medical Research Council Lung Cancer Working Party. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or ten fractions. Br. J. Cancer63(2), 265–270 (1991).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br. J. Cancer65(6), 934–941 (1992).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Lung Cancer Working Party. Randomised trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable NSCLC and good performance status. Clin. Oncol.8(3), 167–175 (1996).
   Google Scholar
• Belderbos JS, Kepka L, Spring Kong F-M, Martel MK, Videtic GM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys.72(2), 335–342 (2008).
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Belderbos JSA, Spring Kong F-M, Kepka L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: small cell lung cancer (SCLC). Int. J. Radiat. Oncol. Biol. Phys.72(2), 327–334 (2008).
   PubMedGoogle Scholar
• Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin. Oncol. (R. Coll. Radiol.)14(5), 338–351 (2002)
   PubMed Web of Science ®Google Scholar
• Kepka L, Danilova V, Saghatelyan T et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer56(2), 235–245 (2007).
   PubMedGoogle Scholar
• Miller RR, McGregor DH. Haemorrhage from carcinoma of the lung. Cancer46(1), 200–205 (1980).
   PubMedGoogle Scholar
• Langendijk JA, Tjwa MK, de Jong JM, ten Velde GP, Wouters EF, Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor? Radiother. Oncol.49(2), 175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Gasinska A, Kolodziejski L, Niemiec J, Dyczek S. Clinical significance of biological differences between cavitated and solid forms of squamous cell lung cancer. Lung Cancer49(2), 171–179 (2005).
   PubMedGoogle Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol.26(28), 4617–4625 (2008).
   PubMed Web of Science ®Google Scholar
• Socinski MA, Crowell R, Hensing TE et al. Treatment of non-small cell lung cancer, stage IV. ACCP evidence-based clinical practice guidelines (2nd edition). Chest132(3 Suppl.), 277S–289S (2007).
   PubMedGoogle Scholar
• Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst. Rev.18(4), CD002143 (2006).
   Google Scholar
• Nestle U, Nieder N, Walter K et al. A palliative accelerated irradiation regimen for advanced non-small cell lung cancer vs. conventionally fractionated 60 Gy: results of a randomized equivalence study. Int. J. Radiat. Oncol. Biol. Phys.48(1), 95–103 (2000).
   PubMedGoogle Scholar
• Sundstrom S, Bremnes R, Aasebo U et al. Hypofractionated palliative radiotherapy (17 Gy per 2 fractions) in advanced non-small cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national Phase III trial. J. Clin. Oncol.22(5), 801–810 (2004).
   PubMed Web of Science ®Google Scholar
• Erridge SC, Gaze MN, Price A et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin. Oncol.17(1), 61–67 (2005).
   PubMedGoogle Scholar
• Salvo N, Hadi S, Napolskikh J, Goh P, Sinclair E, Chow E. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer. A literature review. Curr. Oncol.16(2), 16–28 (2009).
   PubMedGoogle Scholar
• Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int. J. Radiat. Oncol. Biol. Phys.47(1), 149–155 (2000).
   PubMedGoogle Scholar
• Reinfuss M, Glinski B, Kowalska T et al. [Radiotherapy in stage III, unresectable, asymptomatic non-small cell lung cancer. Final results of a prospective randomized study of 240 patients]. Cancer Radiotherapie3(6), 475–479 (1999).
   PubMedGoogle Scholar
• Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int. J. Radiat. Oncol. Biol. Phys.11(4), 751–758 (1985).
   PubMedGoogle Scholar
• Teo P, Tai TH, Choy D, Tsui KH. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys.41(4), 867–871 (1988).
   Google Scholar
• Abratt RP, Shepherd LJ, Salton DG. Palliative radiation for stage 3 non-small cell lung cancer – a prospective study of two moderately high dose regimens. Lung Cancer13(2), 137–143 (1995).
   PubMedGoogle Scholar
• Rees GJ, Devrell CE, Barley VL, Newman HF. Palliative radiotherapy for lung cancer; two versus five fractions. Clin. Oncol.9(2), 90–95 (1997).
   Google Scholar
• Christian E, Adamietz IA, Willach N et al. Radiotherapy in oncological emergencies – final results of a patterns of care study in Germany, Austria and Switzerland. Acta Oncol.47(1), 81–89 (2008).
   PubMed Web of Science ®Google Scholar
• Temel JS, Jackson VA, Billings A et al. Phase II study: integrated palliative care in newly diagnosed advanced non-small cell lung cancer patients. J. Clin. Oncol.25(17), 2377–2382 (2007).
   PubMed Web of Science ®Google Scholar
• Falk S, Girling D, White R et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. Br. Med. J.325(7362), 465–472 (2002).
   PubMedGoogle Scholar
• Sundstrom S, Bremnes R, Brunswing P et al. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother. Oncol.75(2), 141–148 (2005).
   PubMed Web of Science ®Google Scholar
• Cardona AF, Reveiz L, Ospina EG, Ospina V, Yepes A. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst. Rev.16(2), CD004284 (2008).
   Google Scholar
• Ung Y, Yu E, Falkson C et al. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy5(3), 189–202 (2006).
   PubMedGoogle Scholar
• Stout R, Barber P, Burt P et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother. Oncol.56 (3), 323–327 (2000).
   PubMed Web of Science ®Google Scholar
• Moghissi K, Bond MG, Sambrook RJ, Stephens RJ, Hopwood P, Girling DJ. Treatment of endotracheal or endobronchial obstruction by non-small cell lung cancer: lack of patients in an MRC randomized trial leaves key questions unanswered. Medical Research Council Lung Cancer Working Party. Clin. Oncol.11(2), 79–83 (1999).
   Google Scholar
• Huber RM, Fischer R., Hautmann H, Pollinger B, Haussinger K, Wendt T. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int. J. Radiat. Oncol. Biol. Phys.38(3), 533–540 (1997).
   PubMed Web of Science ®Google Scholar
• Langendijk H, de Jong J, Tjwa M et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother. Oncol.58(3), 257–268 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma SC, Behera D, Beriwal S et al. Evaluation of addition of endobronchial brachytherapy for symptoms relief in locally advanced bronchogenic carcinoma. A prospective randomized study. J. Clin. Radiother. Oncol.2(1), 14–19 (2002).
   Google Scholar
• Sur R, Donde B, Mohiuddin M et al. Randomized prospective study on the role of high dose rate intraluminal brachytherapy (HDRILBT) in palliation of symptoms in advanced non small cell lung cancer (NSCLC) treated with radiation alone. Int. J. Radiat. Oncol. Biol. Phys.60(1 Suppl. 1), 127S (2004).
   Google Scholar
• Villanueva AG, Lo TCM, Beamis JF. Endobronchial brachytherapy. Clin. Chest Med.16(3), 445–454 (1995).
   PubMed Web of Science ®Google Scholar
• Escobar-Sacristan JA, Granda-Orive JI, Gutierrez Jimenez T, Delgado JM, Rodero Banos A, Saez Valls R. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur. Respir. J.24(3), 348–352 (2004).
   PubMedGoogle Scholar
• Skowronek J, Kubaszewska M, Kanikowski M, Chichel A, Mlynarczyk W. HDR endobronchial brachytherapy (HDRBT) in the management of advanced lung cancer – comparison of two different dose schedules. Radiother. Oncol.93(3), 436–440 (2009).
   PubMedGoogle Scholar
• Kaasa S, Thorud E, Host H, Lien HH, Lund E, Sjolie I. A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer. Radiother. Oncol.11(1), 7–13 (1988).
   PubMedGoogle Scholar
• Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev. Anticancer Ther.9(10), 1365–1378 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fosella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Milicic B et al. Short-term chemotherapy and palliative radiotherapy for elderly patients with stage IV non-small cell lung cancer: a Phase II study. Lung Cancer24(1), 1–9 (1999).
   PubMedGoogle Scholar
• Michael M, Wirth A, Ball DL et al. A Phase I trial of high-dose palliative radiotherapy plus concurrent weekly vinorelbine and cisplatin in patients with locally advanced and metastatic NSCLC. Br. J. Cancer93(6), 652–661 (2005).
   PubMedGoogle Scholar
• Nawrocki S, Rucinska M, Krzakowski M. Palliative chemoradiotherapy is superior to palliative radiotherapy in stage IIIA – IIIB non-small cell lung cancer patients not eligible for radical treatment – final results of randomized Phase II study. J. Thorac. Oncol.4 (9 Suppl. 1), 702–703 (2009) (Abstract 1226).
   PubMedGoogle Scholar
• Green N, Melbye RW. Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer49(5), 865–868 (1982).
   PubMedGoogle Scholar
• Jackson MA, Ball DL. Palliative retreatment of locally-recurrent lung cancer after radical radiotherapy. Med. J. Aust.147(8), 391–394 (1987).
   PubMedGoogle Scholar
• Montebello JF, Aron BS, Manatunga AK, Horvath JL, Peyton FW. The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation. Am. J. Clin. Oncol.16(6), 482–488 (1993).
   PubMedGoogle Scholar
• Gressen EL, Werner-Wasik M, Cohn J, Topham A, Curran WJ Jr. Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am. J. Clin. Oncol.23(2), 160–163 (2000).
   PubMedGoogle Scholar
• Okamoto Y, Murakami M, Yoden E et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.52(2), 390–396 (2002).
   PubMedGoogle Scholar
• Wu KL, Jiang GL, Qian H et al. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective Phase I–II clinical trial. Int. J. Radiat. Oncol. Biol. Phys.57(5), 1345–1350 (2003).
   PubMedGoogle Scholar
• Kramer GW, Gans S, Ullmann E, van Meerbeeck JP, Legrand CC, Leer JW. Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int. J. Radiat. Oncol. Biol. Phys.58(5), 1388–1393 (2004).
   PubMedGoogle Scholar
• Tada T, Fukuda H, Matsui K et al. Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int. J. Clin. Oncol.10(4), 247–250 (2005).
   PubMedGoogle Scholar
• Ebara T, Tanio N, Etoh T, Shichi I, Honda A, Nakajima N. Palliative re-irradiation for in-field recurrence after definitive radiotherapy in patients with primary lung cancer. Anticancer Res.27(1B), 531–534 (2007).
   PubMed Web of Science ®Google Scholar
• Cetingoz R, Arican-Alicikus Z, Nur-Demiral A, Durmak-Isman B, Bakis-Altas B, Kinay M. Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature. J. BUON14(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Timmerman R, Galvin J, Michalski J et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol.45(7), 779–786 (2006).
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple body sites. J. Clin. Oncol.25(8), 947–952 (2007).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Ariagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N. Engl. J. Med.327(23), 1618–1624 (1992).
   PubMed Web of Science ®Google Scholar
• Kepka L, Sprawka A, Casas F, Abdel-Wahab S, Agarwal JP, Jeremic B. Radiochemotherapy in small-cell lung cancer. Expert Rev. Anticancer Ther.9(10), 1379–1387 (2009).
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol.15(5), 2090–2096 (1997).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a Phase II study. Cancer82(5), 836–841 (1998).
   PubMedGoogle Scholar
• Murray N, Grafton C, Shah A et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J. Clin. Oncol.16(10), 3323–3328 (1998).
   PubMedGoogle Scholar